Neoadjuvant therapy for melanoma: is it ready for prime time?

Lancet Oncol. 2019 Jul;20(7):892-894. doi: 10.1016/S1470-2045(19)30377-8. Epub 2019 Jun 3.

Authors

Beth Helmink¹, Jennifer A Wargo²

Affiliations

¹ Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 77030.
² Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 77030; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA 77030. Electronic address: jwargo@mdanderson.org.

PMID: 31171445
DOI: 10.1016/S1470-2045(19)30377-8

No abstract available

Publication types

Comment

MeSH terms

Humans
Ipilimumab
Melanoma*
Neoadjuvant Therapy
Nivolumab
Skin Neoplasms*

Substances

Ipilimumab
Nivolumab